Perbedaan Polimorfisme Monosit Chemoattractant Protein -1 -2518A/G pada Orang dengan Skizofrenia dan Kontrol Sehat Suku Batak

Abstract

Background: Monocyte chemoattractant protein-1 (MCP-1) -2518 A/G polymorphism affects the MCP-1 gene expression, hence, may alter inflammatory response in individuals. Studies indicated that this polymorphism contributes to susceptibility of developing schizophrenia. Schizophrenia is a complex and multifactorial condition, involving the interaction between genetic and environmental factors. Recent studies suggested that individuals with the G allele of the MCP-1 -2518 A/G polymorphism have a higher risk of developing schizophrenia compared to individuals with homozygous A allele. Further studies are needed to understand the relationship between the role of MCP-1 -2518 A/G polymorphism in susceptibility of schizophrenia. Method: Samples were collected using non-probability purposive sampling. A total of 400 Bataknese individuals (200 for each schizophrenia and control ) participated in the study. The MCP-1 -2518A/G polymorphism was determined using the PCR-RFLP technique. Results: There was no significant difference in the frequency of A and G alleles between schizophrenia and control group (OR = 0.82, p = 0.2). However, there was a significant association between the genotypes (AG vs GG) with a p-value of <0.01 and an OR of 3.167 with a CI between 1.889 to 5.311. There was no significant association between the genotypes (AA vs GG) with a p-value of 0.157, an OR of 1.557 with a CI of 0.085 to 0.633. Conclusion: In this study, we found that the MCP-1 -2518A/G polymorphism may be associated with the risk of developing schizophrenia. However, further studies are needed to understand the interrelational mechanism of MCP-1 and schizophrenia. The MCP-1 -2518A/G polymorphism may be an additional risk factor in the development of schizophrenia and may be used as a biomarker in the diagnosis and treatment of schizophrenia in the future.